Research Index

BPC-157 Research Index

PSI surfaces 50 peer-reviewed studies on BPC-157, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.

Sort

Type

Condition

50 studies

Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.

Zhang H, Shao L, Feng Q et al.

Appl Biochem Biotechnol·2026·Animal·PubMed →

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

Tewari K, Liu TP, Im C et al.

Am J Sports Med·2026·Animal·PubMed →

Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel.

Arunim, Dagar M, Solanki M et al.

3 Biotech·2026·Animal·PubMed →

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.

Biçer O, Adanir O, Güleryüz Y et al.

Jt Dis Relat Surg·2026·Animal·Tendon & Ligament, Wound Healing·PubMed →

Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats.

Vukoja I, Vlainic J, Francina M et al.

J Physiol Pharmacol·2026·Animal·Antimicrobial·PubMed →

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach.

Smoday IM, Vukovic V, Oroz K et al.

Pharmaceuticals (Basel)·2026·Animal·PubMed →

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.

Mazzarino M, Colpaert T, Deventer K et al.

Analyst·2026·Animal·PubMed →

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.

Jelińska J, Józwiak M, Szeleszczuk Ł et al.

Int J Mol Sci·2026·Animal·PubMed →

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

Yıldırım AK, Demirtaş H, Özer A et al.

Sci Rep·2026·Animal·PubMed →

Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.

Yildirim AK, Dastan AO, Demeli Ertus M et al.

J Clin Med·2026·Animal·PubMed →

Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.

Grubisic MM, Strbe S, Barisic I et al.

Curr Neuropharmacol·2026·Animal·PubMed →

Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.

Smoday IM, Vukovic V, Oroz K et al.

Pharmaceuticals (Basel)·2026·Animal·PubMed →

Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.

Madzarac G, Becejac T, Penovic T et al.

Pharmaceuticals (Basel)·2026·Animal·PubMed →

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

Lee E, Burgess K

Altern Ther Health Med·2025·Human·PubMed →

Editorial Commentary: Testosterone, Growth Hormone, and Vitamin D Supplementation Is Not Routinely Indicated for Orthopaedic Surgery Patients.

Dekker TJ

Arthroscopy·2025·Human·GH Activity·PubMed →

Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".

Józwiak M, Bauer M, Kamysz W et al.

Pharmaceuticals (Basel)·2025·Animal·PubMed →

BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.

Sikiric P, Seiwerth S, Skrtic A et al.

Pharmaceuticals (Basel)·2025·Animal·PubMed →

Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).

Whitehouse M

Inflammopharmacology·2025·Animal·PubMed →

Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.

Demirtaş H, Özer A, Yıldırım AK et al.

Medicina (Kaunas)·2025·Animal·Liver Protection·PubMed →

Withdrawn: Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.

Grubisic MM, Strbe S, Barisic I et al.

Curr Neuropharmacol·2025·Animal·PubMed →

Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats.

Matek D, Matek I, Staresinic E et al.

Pharmaceutics·2025·Animal·PubMed →

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.

DiStefano MJ, Dardouri M, Moore GD et al.

J Pharm Policy Pract·2025·Animal·PubMed →

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

Lee E, Walker C, Ayadi B

Altern Ther Health Med·2024·Human·PubMed →

Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.

Vukusic D, Zenko Sever A, Sever M et al.

J Physiol Pharmacol·2024·Animal·PubMed →

Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

Tepes M, Krezic I, Vranes H et al.

Pharmaceuticals (Basel)·2023·Animal·PubMed →

Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.

Tian T, Jing J, Li Y et al.

Molecules·2023·Animal·PubMed →

Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats.

Smoday IM, Krezic I, Kalogjera L et al.

Pharmaceuticals (Basel)·2023·Animal·PubMed →

Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect.

Kalogjera L, Krezic I, Smoday IM et al.

World J Gastroenterol·2023·Animal·PubMed →

Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy.

Premuzic Mestrovic I, Smoday IM, Kalogjera L et al.

Pharmaceuticals (Basel)·2023·Animal·PubMed →

Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy.

Strbe S, Smoday IM, Krezic I et al.

Pharmaceuticals (Basel)·2023·Animal·PubMed →

Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways.

Sikiric P, Gojkovic S, Knezevic M et al.

Curr Med Chem·2023·Animal·PubMed →

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.

He L, Feng D, Guo H et al.

Front Pharmacol·2022·Animal·PubMed →

Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157.

Gamulin O, Oroz K, Coric L et al.

Biomedicines·2022·Animal·PubMed →

Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro.

Huang BS, Huang SC, Chen FH et al.

Life Sci·2022·Animal·PubMed →

BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia.

Zemba Cilic A, Zemba M, Cilic M et al.

Biomedicines·2022·Animal·PubMed →

Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats.

Smoday IM, Petrovic I, Kalogjera L et al.

Biomedicines·2022·Animal·PubMed →

Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy.

Perovic D, Milavic M, Dokuzovic S et al.

Curr Issues Mol Biol·2022·Animal·PubMed →

The anti-nociceptive effect of BPC-157 on the incisional pain model in rats.

Jung YH, Kim H, Kim H et al.

J Dent Anesth Pain Med·2022·Animal·PubMed →

Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.

Barisic I, Balenovic D, Udovicic M et al.

Biomedicines·2022·Animal·PubMed →

Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome.

Sikiric P, Skrtic A, Gojkovic S et al.

World J Gastroenterol·2022·Animal·PubMed →

Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-N(G)-nitro-L-arginine methyl ester worsening.

Bilic Z, Gojkovic S, Kalogjera L et al.

J Physiol Pharmacol·2021·Animal·PubMed →

Corrigendum: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.

Tepes M, Gojkovic S, Krezic I et al.

Front Pharmacol·2021·Animal·PubMed →